Cigna Covering XDx's AlloMap Test | GenomeWeb

NEW YORK (GenomeWeb News) – XDx said this week that health insurer Cigna has issued a positive coverage decision for XDx's AlloMap Molecular Expression Testing for potential heart transplant rejection.

The policy, which took effect immediately, applies to about 13.8 million lives covered by Cigna. Barry Kane, senior director of finance and reimbursement at XDx, said the firm is "particularly pleased" that Cigna is formally covering AlloMap for patients six months to five years post-heart transplant.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.